Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NBTX-001
- Development stage
- Unknown
- Lead developer
- Nobilis Therapeutics
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
NBTX-001 is a drug-device combination specifically designed to deliver xenon gas through a proprietary portable inhalation device. It functions as an NMDA receptor antagonist, with xenon atoms interacting with aromatic amino-acid residues on NMDA receptors to provide highly specific and controllable antagonism. The drug also blocks AMPA, nACh (α4β2), 5-HT3, plasma membrane Ca2+ ATPase and increases inhibitory neurotransmission by stimulating GlyR1 and TREK-1 potassium channel. It has been shown to reduce pro-inflammatory cytokines and increase pro-survival factors. NBTX-001 is being developed primarily for psychiatric disorders, with the most advanced development in post-traumatic stress disorder (PTSD) and panic disorder.
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)AMPAR (AMPA receptor)GLYR1 (Glyoxylate reductase 1 homolog)NMDAR (Glutamate receptor ionotropic, NMDA)α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)PMCA (Plasma membrane Ca2+-transporting ATPase)KCNK2 (Potassium channel subfamily K member 2)GLRA1 (Glycine receptor subunit Alpha-1)PMCA (Plasma membrane calcium ATPase)
Beyond the preview
Go deeper on NBTX-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NBTX-001.